Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, 2-Part, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Proof-of-Concept, Dose-Finding Study Evaluating the Efficacy and Safety of CNTO 136 Administered Subcutaneously in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy.

Next Previous
Trial Profile

A Phase 2, 2-Part, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Proof-of-Concept, Dose-Finding Study Evaluating the Efficacy and Safety of CNTO 136 Administered Subcutaneously in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sirukumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Centocor

Most Recent Events

  • 01 Sep 2015 Results assessing efficacy of sirukumab on measures of core depressive symptoms and fatigue presented at the 28th Annual Congress of the European College of Neuropsychopharmacology (n = 176).
  • 13 Jun 2015 Results (post-hoc analysis) presented at the 16th Annual Congress of the European League Against Rheumatism.
  • 03 Apr 2014 Results published in the Annals of the Rheumatic Diseases.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top